Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: pacritinib Clear all

Conditions: Advanced Lung Adenocarcinoma
Interventions: bemcentinib, pacritinib; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Myelomonocytic Leukemia
Interventions: Pacritinib, Azacitidine; Drug
Lead sponsor: Douglas Tremblay; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Graft Vs Host Disease, GVHD
Interventions: Pacritinib, Sirolimus, Tacrolimus, Allogenic hematopoietic cell transplant (alloHCT); Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • Minneapolis, Minnesota

Conditions: Graft vs Host Disease
Interventions: Pacritinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Miami, Florida • Bethesda, Maryland

Conditions: T-Cell Neoplasm, Lymphoproliferative Disorders
Interventions: Pacritinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 6
States / cities: Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more

Conditions: Prostate Cancer
Interventions: Pacritinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Healthy
Interventions: Treatment A: 400 mg Pacritinib P3CT, Treatment B: 400 mg of pacritinib FMI; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Interventions: Pacritinib, Decitabine, Decitabine and Cedazuridine, Azacitidine, Survey Administration, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy; Drug · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Decitabine, Ruxolitinib, Fedratinib, Questionnaire Administration, Pacritinib, Biospecimen Collection; Drug · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions: Pacritinib, Ibrutinib; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Rochester, Minnesota

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Physician's Choice medications; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more

Conditions: Colorectal Cancer
Interventions: Pacritinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions: Pacritinib, Erlotinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myelodysplastic Syndromes
Interventions: pacritinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 33
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more

Conditions: Myelofibrosis (MF)
Interventions: Not applicable- observational study; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: New Haven, Connecticut • Columbus, Ohio • Charleston, South Carolina

Conditions: COVID19, COVID-19, COVID
Interventions: Pacritinib, Placebo; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Orange, California • Jacksonville, Florida • Atlanta, Georgia + 16 more

Conditions: E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome, VEXAS, Vexas Syndrome
Interventions: Pacritinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Antitumor Drug Screening Assay, Dasatinib, Idelalisib, Laboratory Biomarker Analysis, Pacritinib, Pharmacological Study, Ponatinib, Ponatinib Hydrochloride, Ruxolitinib, Sorafenib, Sorafenib Tosylate, Sunitinib, Sunitinib Malate; Other · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma

Pacritinib in CMML

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Pacritinib Effectiveness in Real-world Settings

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia